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Integrative molecular and functional profiling of ERBB2-amplified breast 
cancers identifies new genetic dependencies 
K-K Shiu1, D Wetterskog1, A Mackay1, R Natrajan1, M Lambros1, D Sims1, I Bajrami1, R Brough1, J Frankum1, R Sharpe1, C 
Marchio2, 
H Horlings3, F Reyal3, M van der Vijver3, N Turner1, JS Reis-Filho1, CJ Lord1 and A Ashworth1 
Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 
15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a 
marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant 
clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling 
has demonstrated that ERBB2þve breast cancers are distinguished from ERþve and ‘triple-negative’ 
breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-
amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes 
may have important roles in influencing clinical outcome, and could represent genetic 
dependencies in ERBB2þve cancers and therefore potential therapeutic targets. Here, we describe 
an integrated genomic, gene expression and functional analysis to determine whether the genes 
present within amplicons are critical for the survival of ERBB2þve breast tumour cells. We show 
that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 
oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. 
These include an addiction to the transcription factor gene TFAP2C when it is amplified and 
overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2þve breast 
cancer cells. 
Keywords: HER2-positive breast cancer; microarrays; gene expression; comparative genomic 
hybridization; siRNA screens; TFAP2C 
INTRODUCTION 
Amplification and overexpression of the gene encoding the receptor tyrosine kinase ERBB2 is 
present in around 15% of all breast cancers, and is associated with aggressive disease and poor 
clinical outcome. Anti-ERBB2-targeted therapies such as trastuzumab and lapatinib have been 
shown to significantly increase the survival of patients with ERBB2þve cancer,1,2 but de novo 
resistance is common with response rates of B30% in the metastatic setting.3 Therefore, the positive 
predictive value of ERBB2 amplification/ overexpression for trastuzumab sensitivity is relatively 
low. 
Furthermore, acquired resistance to trastuzumab inevitably occurs in the metastatic setting as 
represented by a progression-free survival benefit of only 2.2 months when compared with standard 
chemotherapy.1 In the adjuvant setting, relapse-free survival is significantly prolonged with 
trastuzumab–chemotherapy combinations, 
4,5 although overall survival benefits may be somewhat lower than first hoped6,7 Therefore, the 
identification of additional drivers of ERBB2þve cancer is required, and better prognostic and 
predictive biomarkers are needed. 
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At the genomic level, ERBB2-amplified breast cancers display complex genome profiles and a 
number of discrete gene 
amplification events. For example, amplifications of genetic material at chromosomes 1q, 8q, 17q 
and 20q are relatively 
common events in ERBB2-amplified breast tumours.8–10 However, with the exception of ERBB2 
itself, the biological significance of these additional amplification events is not yet clear. Some of 
these amplicons most likely encompass bona fide oncogenes and candidate therapeutic targets.11,12 
Here, we describe an integrated genetic, transcriptomic and functional analysis of a wide panel of 
genes amplified and overexpressed in ERBB2þve breast tumours and the identification of additional 
genetic dependencies in ERBB2þve breast cancer models. 
RESULTS 
ERBB2-amplified breast cancers are heterogeneous at the genomic level 
To investigate the significance of amplification events in ERBB2þ ve breast cancer we used an 
integrated approach. In summary, this involved (i) generating genomic and transcriptomic profiles 
of a well-curated panel of primary breast cancers harbouring ERBB2 gene amplification; (ii) 
integrating these data to identify effects where gene amplification corresponded with high-level 
expression of the same gene; and (iii) the use of high throughput RNA interference screening to 
functionally assess whether genes that are amplified and overexpressed are also essential for tumour 
cell 
survival. To analyse the genomic composition of ERBB2þve breast tumours, we used a high-
resolution Array-based Comparative Genome Hybridization (aCGH) platform. This platform has a 
resolution of 50 kb and has previously been used to identify subsequently validated gene copy 
number aberrations in other human tumours.13–15 Using this platform, we profiled DNA extracted 
from 58 primary, fresh frozen, ERBB2-amplified breast cancers. To minimise the confounding 
effects of stromal material,16 all tumours were either determined by light microscopy to contain 
over 70% tumour content or microdissected to remove stromal contamination, ensuring at least 70% 
of tumour cell content in the final dissected material. 
The main clinicopathological characteristics of these tumours are described in Supplementary Table 
S1. All tumours were from patients who had not received neoadjuvant therapy. ERBB2 
overexpression in each tumour had been previously defined by immunohistochemistry (3þ) and 
ERBB2 amplification confirmed by chromogenic in situ hybridization (CISH) and/or aCGH to a 
381 kb smallest region of amplification on 17q12; 34.98–35.36 Mb 
(Supplementary Figure 1). 
The majority of tumours exhibited a ‘firestorm’ genomic pattern17 characterized by multiple 
discrete amplifications 
(Figure 1ai, data available on the ROCK database18 (www.rock.icr.ac.uk)), supporting previous 
observations.10,19 We also noted a small number of tumours (7/58, 12%) that displayed a 
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‘sawtooth’ pattern17 (Figure 1aii), which is reported to be more commonly associated with basal-
like/triple-negative breast cancers.20 
The number of amplifications seen in each tumour was variable (mean¼13 s.d.þ/_6.6, range 1–34). 
In total, 122 discrete and recurrent loci (nX2) of high-level gains and/or amplicons were identified 
(Figure 1bi). Consistent with previous studies,10,19 the most prevalent regions of amplification 
included 8q24 (8.8% of all tumours), 11q13 (11%) and 20q13 (13%). In our analysis we also noted 
moderate differences between the ERBB2þ/ERþ and ERBB2þ/ER_ tumour subgroups. Although 
only 0.87% of the genome was differentially gained, lost or amplified, loss of 14q32.2 was 
significantly more prevalent (Po0.05 Fisher’s exact test adjusted for multiple comparisons in the 
ERBB2þ/ER_ subgroup when compared with the ERBB2þ/ERþ subgroup. Amplification of 17q12 
(Start; End 32.82:33.21 Mb) was significantly more prevalent in ERBB2þ/ERþve tumours (Po0.05) 
as shown in Supplementary Table S2. 
This genomic profiling confirmed previous suggestions10,19 that, rather than being homogeneous 
at the genomic level, ERBB2-amplified breast tumours exhibit a significant level of genomic 
heterogeneity, though not greatly influenced by oestrogen receptor (ER) status, perhaps explaining 
the variable clinical behaviour of ERBB2þve disease. 
Integration of genomic and transcriptomic data from ERBB2-amplified tumours  
On the basis of the ERBB2 paradigm, where gene addiction effects may be represented by gene 
amplification that drives high-level expression, our aim was to identify similar ‘driver’ genes within 
the multiple amplicons we had identified.21 RNA of sufficient quality was available from most 
(76%, 45/58) of the tumours, which we had genomically characterized and so these were profiled 
using gene expression microarrays as previously described.14,22 
We used two parallel methods to select genes within amplicons to functionally validate: (i) a 
Pearson’s correlation to determine the genes whose expression was significantly associated with 
changes in gene copy number and (ii) a Mann–Whitney U-test to assess correlation between 
transcript levels and amplification status as previously described.23 Genes identified as having 
significant correlation between copy number/amplification and expression using either statistical 
method totalled 511 (Figures 2a and b and Supplementary Table S3). In the 45 tumours, 93 unique 
recurrent (nX2) amplicons were identified (Figure 2c). The majority of genes (323, 63%) were 
identified using both methods included MTDH, PPM1D, RPS6KB1 and AURKA. The oncogenic 
nature of many of these genes has been previously demonstrated,13,24,25 suggesting that using this 
approach may constitute a valid approach for the identification of additional candidate drivers in 
ERBB2-amplified tumours. A total of 168 genes exclusively identified using Pearson’s correlation 
(168, 33%) included ERBB2, GRB7 and STARD3 on the ERBB2 amplicon, and MYC and 
ZNF217 on 8q24 and 20q13, respectively. An additional 20 genes (4%) were exclusively identified 
using the Mann–Whitney U-test and included CCND1, RAB34 and ORAOV2. 
Genomic and transcriptomic profiling of an ERBB2-amplified breast tumour cell line panel  
We aimed to identify amplified and overexpressed genes in ERBB2-amplified tumours and 
functionally assess the possibility that these same genes were also essential for tumour cell survival 
and, therefore, be candidate therapeutic targets. To define suitable models for high throughput short 
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interfering RNA (siRNA) screening, we compiled a panel of 14 ERBB2-amplified and 9 non-
ERBB2-amplified breast cancer cell lines and characterized this panel by aCGH and expression 
arrays in a similar fashion to the tumour collection.18 As observed in the tumours, the 14 ERBB2-
amplified cell lines exhibited multiple recurrent amplifications (n¼67), although common 
amplicons on 1q, 8q, 11q, 17q and 20q were again noted (Figure 1bii) and all displayed a 
‘firestorm’ pattern. In addition, the ERBB2, ER and progesterone receptor status of these cell lines 
was defined by CISH and immunohistochemistry on a customised cell line microarray (Figures 3a–
c). Finally, we also used viability profiling to define the sensitivity of each cell line to the small 
molecule ERBB2 inhibitor, lapatinib Figure 3d). 
Functional profiling in ERBB2-amplified breast tumour models  
Analysis of the aCGH and expression profiles of tumour cell lines suggested that 72% (369/511) of 
the amplified/overexpressed genes identified in the primary tumour analysis were also amplified in 
at least two cell lines (Figure 2c and Supplementary Table S3). To establish the functional 
significance of amplified/overexpression effects in ERBB2-amplified tumours, we optimised high 
throughput RNA interference screening procedures in a panel of ERBB2-amplified tumour cell 
lines (see Methods). 
In addition to several ERBB2-amplified tumour lines we included a number of non-ERBB2-
amplified breast tumour models as controls. In brief, cell lines were reverse transfected with siRNA 
targeting each gene in a 96-well plate format and cell viability determined 7 days later using Cell 
TitreGlo (Promega, Madison, WI, USA), which measures cellular ATP. To identify optimal 
screening conditions, cell number, siRNA concentration and duration of the screen were optimised 
to obtain (i) o10% reduction in viability in cells transfected with a control, non-targeting siRNA 
when compared with mock (no siRNA)-transfected cells; (ii) high efficiency of transfection, as 
defined by 470% loss of viability in cells transfected with siRNA targeting the essential kinase 
PLK1; and (iii) o90% cell confluency at 7 days post transfection, so as to maximize the possibility 
of identifying loss of viability effects. As far as was possible, cell lines with similar doubling times 
(maximum 48 h) were selected for screening so as to minimise the impact of differential 
proliferation rates across the screen as a whole. Cell lines excluded from further siRNA screening as 
they failed growth time criteria were SUM190, UACC812 and UACC893. 
Following optimisation, each cell line was screened in triplicate using a siRNA library targeting the 
369 genes previously identified as amplified/overexpressed in primary ERBB2þve breast cancers 
and also amplified in at least two ERBB2þve cell lines. The siRNA screening library was composed 
of one SMARTPool (Dharmacon, Lafayette, CO, USA) per well, where each SMARTPool 
consisted of four different siRNA species, all targeting the same gene. Cell viability data from each 
replicate screen was standardized using a Z-score/median absolute deviation approach where 
negative Z-scores represented cell inhibitory effects caused by siRNA transfection.26 The quality of 
each screen was assessed by the performance of non-targeting siRNA (siCON) and siRNA targeting 
PLK1 with the subsequent calculation of a dynamic range z027 for each screen (Figures 4a–c). The 
extent of replication between triplicate screens was assessed by Spearman’s correlation coefficients 
(r2), and in each case we observed r2 of 40.7 for each replica comparison, suggesting highly 
reproducible data. In addition, unsupervised clustering of Z-score data also showed that 
experimental triplicates for each cell line clustered together with 100% concordance (Figure 4d). In 
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total, these quality metrics suggested that the effects observed were reproducible and robust, and 
that we were able to confidently compare viability effects across the panel of cell lines 
(Supplementary Table S5). 
Ten ERBB2-amplified cell lines were used in the initial siRNA screen and six non-ERBB2-
amplified cell lines were used as controls. Following robust quality control, two ERBB2-amplified 
cell lines—MDAMB453 and SUM225—were excluded from the analysis as the separation of 
negative and positive controls as assessed by z0 was inadequate. A Z-score ofp_2 was used as the 
threshold for defining significant cell inhibitory effects in each screen, where Zp_2 is approximately 
equal to a chance probability, Q, ofo0.02 (1 in 44) in each screen and Q¼(0.02)3 for effects that 
occurred in all three replica screens. Using this threshold, 128 siRNAs inhibited growth of at least 
one cell line and 72 siRNAs inhibited at least two cell lines. There were 20 siRNAs that inhibited at 
least half of the panel. The top hits ranked by Z-score for each cell line are shown in Supplementary 
Table S6. As a general observation, we did note that the functional viability profiles of the ERBB2-
amplified cell lines were relatively diverse and only 20 siRNAs elicited inhibition in at least half the 
panel of 14 cell lines. This was perhaps expected, given the relative genetic heterogeneity of 
ERBB2-amplified primary tumours and cell lines. 
Correlation of functional viability profiles with genomic and transcriptomic profiles As proof of 
principle that our approach could identify genetic dependencies in ERBB2-amplified breast cancer, 
we integrated genomic, transcriptomic and functional data for the ERBB2 gene itself. Although all 
ERBB2þve cell lines showed ERBB2 amplification and overexpression, only the viability of three 
(BT474, SKBR3 out type II or b errors for the identification of genes that were consistently 
overexpressed when amplified. To avoid the exclusion of potential drivers solely on statistical 
grounds, we also searched for recurrently amplified genes whose siRNA silencing caused 
significant loss of cell viability in at least two cell lines. These genes are shown in Table 1. Of these 
genes, TFAP2C was amplified and overexpressed in BT474 and SKBR3 (Supplementary Figure 
4a). TFAP2C amplification and overexpression in these models was confirmed using a CISH probe 
and a specific antibody to TFAP2C on our cell line microarray (Figure 6c), as well as by western 
blot analysis (Supplementary Figure 4b). We also observed a significant correlation between 
TFAP2C copy number gain and amplification/overexpression in our tumour cohort (Supplementary 
Figure 4c). Furthermore, in our entire 58 ERBB2þ ve primary breast cancer data set, three tumours 
exhibited TFAP2C amplification and 26 exhibited TFAP2C copy number gain 
(www.rock.icr.ac.uk). To eliminate possible off target effects of siRNA, we then repeated the 
screen with three independent siRNAs to TFAP2C across nine ERBB2-amplified cell lines. We 
found that these three siRNAs and the original siRNA smart pool significantly inhibited two cell 
lines BT474 and SKBR3 (Figures 6a and b). To validate this finding, we transfected each siRNA 
duplex into BT474 and SKBR3 cells to establish the gene-silencing effect. 
Three siRNAs significantly reduced TFAP2C protein levels 72 h following transfection (Figure 6d). 
In addition, silencing of TFAP2C caused significant apoptosis as shown by an increase in PARP 
cleavage (Figure 6d) and caspase activity (Supplementary Figure 5). Taken together, this suggested 
that TFAP2C when amplified and overexpressed is a potential oncogenic driver when co-amplified 
with ERBB2, and that its silencing causes cell death via an apoptotic pathway. 
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We also assessed the possibility that the effect of reducing TFAP2C could be caused by affecting 
ERBB2 expression as previous studies have shown that TFAP2C can bind to promoter regions 
upstream and downstream of ERBB230,31 and affect ERBB2 transcriptional activity.32 Therefore, 
we transfected three independent siRNAs that targeted TFAP2C into BT474 and SKBR3 cells. This 
resulted in decreased ERBB2 protein expression after 72 h (Figure 6d). However, the expression of 
ERBB2 cDNA via a heterologous promoter did not ostensibly alter the cell inhibitory or 
proapoptotic effects of TFAP2C siRNA (Supplementary Figures 5 and 6), suggesting that the 
inhibitory effect of TFAP2C silencing may not entirely be mediated by an effect on ERBB2 levels. 
DISCUSSION 
In this study, we have assessed the multiple genetic dependencies of ERBB2-amplified breast 
cancers, using a combination of genomic profiling and parallel functional analysis in multiple breast 
cancer cell lines. The integration of genomic and transcriptomic profiling in our study highlights the 
genomic heterogeneity in this breast cancer subtype. Although this genomic heterogeneity might 
underpin the variable clinical outcomes for patients with this aggressive disease, we reasoned that 
focussing upon those genes that are recurrently amplified and overexpressed in ERBB2þve breast 
tumours might be a route to identify additional genes that are critical for the survival of ERBB2þve 
breast tumour cells. Using this approach of integrated molecular and functional profiling we 
identified a number of genetic dependencies, most notably an effect involving the transcription 
factor gene TFAP2C. In models where TFAP2C is amplified and overexpressed, TFAP2C silencing 
by siRNA causes inhibition of cell growth, most likely by inducing apoptosis (Figure 6d). The 
sensitivity of TFAP2C-amplified/overexpressing models to siRNA silencing of this gene and the 
frequency of TFAP2C amplification/overexpression in ERBB2þve breast cancers we only profiled 
biopsies with 470% tumour content in order to avoid biases associated with stromal cell/non-
neoplastic cell contamination. This approach could have increased the level of sensitivity in terms 
of detecting recurrent amplicons; (ii) although ERBB2-amplified tumours profiled in this study had 
a predominantly ‘firestorm’ genomic pattern, in keeping with previous reports,17 we observed that 
those ERBB2-amplified tumours with a ‘sawtooth’ genomic profile were predominantly 
ER_ve/ERBB2þve. Sawtooth patterns have been reported to be associated with a basal-like/’triple-
negative’ phenotype and underlying DNA repair deficiencies13,23 rather than ERBB2-amplified 
tumours. Furthermore, we are currently the only study that has used the genomic and transcriptional 
aberrations observed in this breast cancer subtype and integrated this with functional profiling via 
high throughput siRNA screens. These findings emphasize how the genomically heterogeneous 
ERBB2-amplified breast cancers are even within this phenotypic subgroup, and may explain why 
patients diagnosed with ERBB2þve breast cancers have differing clinical outcomes despite 
receiving similar therapies.6,7  
This is the first study to identify TFAP2C (AP2g) as being essential for cell survival in a subgroup 
of ERBB2-amplified breast tumour models defined by TFAP2C amplification and overexpression. 
Previously, a number of observations have linked TFAP2C expression to breast cancer. TFAP2C is 
a member of a family of five activating enhancer transcription factors (TFAP2A-G) that are 
essential for normal embryogenesis, as well as being linked to cell proliferation, dfferentiation and 
cell survival.34 TFAP2C is located on 20q13, a region which is copy number gained in B18% of all 
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breast cancers.35 Retrospective studies have correlated high-level TFAP2C expression with high-
grade breast cancers,34 poorer prognosis in patients with invasive breast cancers and resistance to 
hormone therapy.36,37 This may be partly explained by the fact that it has been shown to have 
roles in upregulating ER-mediated gene transcription by mediating long range chromatin 
interactions38 and to act as repressor of transcription by inhibiting CDKN1A, a growth inhibitor.39 
Here we expand these observations and demonstrate that TFAP2C amplification is significantly 
enriched in patients with ERBB2þve breast cancer (29/58, 50%) and that amplification also 
correlates with TFAP2C mRNA overexpression (Supplementary Figure 4a). TFAP2C has been 
shown to bind at multiple promoter sites proximal and distal of the ERBB2 gene,30,31,40 
suggesting a mechanism by which TFAP2C could modulate ERBB2 signalling. Indeed, we show 
here that in ERBB2þve models that are inhibited by TFPA2C siRNA, ERBB2 protein levels are 
suppressed by TFAP2C silencing (Figure 6d). However, as transcription factors are rarely specific 
for single genes, we cannot discount the possibility that the dependency upon TFAP2C that we 
observe is also mediated by modulating the expression of a number of genes.34,38 We do note that 
the expression of ERBB2 cDNA from a heterologous promoter did not reverse the cell inhibitory 
effect of TFAP2C siRNA (Supplementary Figure 6). Notwithstanding the difficulties in replicating 
physiological expression of genes with cDNA expression constructs, it seems possible that this 
result is in keeping with the hypothesis that the dependency on TFAP2C is explained by the activity 
of this transcription factor on a number of genes in addition to ERBB2. 
In addition to identifying TFAP2C as a genetic dependency in ERBB2þve breast cancer, a 
comparative analysis of anti-ERBB drug sensitivity and ERBB2 siRNA sensitivity in ERBB2þve 
breast cancer models confirms that only a small fraction of the ERBB2-amplified breast cancer lines 
are truly addicted to the ERBB2 oncogene.41–43 For example, we have shown that ERBB2þve 
tumour cell line models that are resistant to multiple ERBB2 and pan-ERB-targeted agents are also 
resistant to ERBB2 silencing by siRNA (Figure 5c). Although multiple potential mechanisms of 
acquired and de novo resistance to ERBB2-targeted therapies have been previously 
proposed,42,44–47 few have been validated in prospective clinical trials.47 Our data indicate that 
one fundamental reason for de novo resistance to ERBB2-targeted agents is the loss of dependency 
on the ERBB2 pathway, as opposed to a pharmacological mechanism, such as increased drug efflux 
or metabolism that could impair the ability of a drug to inhibit its target. The clinical implication of 
these data would be that for some patients, the failure to respond to an ERBB2-targeted agent such 
as lapatinib would also predict a poor response to other ERBB2-targeted therapies. We also 
demonstrate that ERBB3 represents a genetic dependency in a subset of ERBB2-amplified models, 
supporting the focus upon this ERBB2 dimer partner as an additional therapeutic target.28,48 Our 
comparative anti-ERB drug/ERBB2 siRNA data indicate, however, that such therapy may only be 
particularly effective in ERBB2þve cancers that remain addicted to ERBB2. Our study also 
highlights the fact that, in general, the functional dependencies in ERBB2þve breast tumour models 
are relatively diverse and that many of the dependencies identified are isolated to a relatively small 
number of models. It seems unlikely that this is an artefact of the RNAi screening approach used 
(for example, the effect of ERBB2 siRNA mirrors the effect of anti-ERB drugs, giving some 
confidence in the validity of the RNAi functional profiling) but perhaps is more reflective of the 
inherent genetic and functional heterogeneity of both the models and the tumours profiled. 
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In conclusion, we propose that TFAP2C amplification and overexpression represents a genetic 
dependency in ERBB2þve breast cancer. Integration of molecular and functional profiling in 
ERBB2þve breast cancer identifies genes that warrant further study. One particular area of focus in 
the future will be to correlate the expression and copy number genes such as TFAP2C in tumour 
biopsy material obtained from large neoadjuvant-targeted therapy trials involving anti-ERBB2-
targeted agents as these become available. 
MATERIALS AND METHODS 
Patient tumour samples 
Fifty-eight fresh frozen ERBB2þve breast cancer samples were obtained after approval by local 
Ethics Committees from the authors’ institutions. All tumours were either ERBB2 2þ or 3þ on 
immunohistochemistry and were confirmed to be amplified with CISH and/or aCGH. All patients 
had stage I–III disease, and samples received were from the primary surgery. None of the tumours 
had received neoadjuvant therapy. Their clinicopathological characteristics are shown in 
Supplementary Table S1. 
All tumours possessed 470% neoplastic cell content and had matching RNA of sufficient quality for 
expression arrays. DNA and RNA were extracted as previously described.13,49,50 ER and 
progesterone receptor status was determined by immunohistochemical analysis using the 6F11 
(1:150) and PgR636 (1:200) antibodies, respectively, as previously described.13,22 The Allred 
scoring system was employed and tumours were considered positive when the score wasX3. HER2 
gene amplification was defined based on CISH analysis using an US Food and Drug Administrator 
approved probe (SpotLight HER2 amplification probe, Invitrogen, Carlsbad, CA, USA) and/ or by 
inspection of the results of aCGH analysis, as previously described.9 
Cancer cell lines 
Fourteen commercially available cell lines known to harbour ERBB2 gene amplification and 9 non-
ERBB2-amplified controls representing the other molecular subtypes of breast cancer were 
selected. They were purchased from ATCC (Manassas, VI, USA) unless otherwise stated, and were 
maintained as per source recommendations. These included CAL51, CAMA1, HCC1143, MCF7, 
MDAMB468, MDAMB231, MCF12A, SUM149 (Asterand), T47D, BT474, HCC202, HCC1569, 
HCC1954, MDA-MB-361, MDAMB-453, SKBR3, UACC-812, UACC-893, ZR-75.30, 
SUM190PT (Asterand) SUM225CWN (Asterand), JIMT-1 (DSMZ) and VP229 (EACC). DNA 
was extracted and purified using DNeasy (Qiagen Ltd, Crawley, West Sussex, UK) total DNA 
purification protocol for cultured animal cells, and quantified using Pico Green. DNA was then 
stored at _20 1C before use. Total RNA was extracted in a RNase-free environment using TRIzol 
(Invitrogen) standard manufacturer’s protocol (Cat No 15596-018). RNA pellets were airdried and 
resuspended in a total volume of 50 ml nuclease-free water (Ambion, Paisley, UK). RNA quality 
and quantity were assessed by using an Eukaryote Total RNA Nano Series II Chip with an Agilent 
2100 Bioanalyser (Winnersh, UK) according to the manufacturer’s instructions, then stored at _80 
1C before use. We used short tandem repeat profiling to verify authenticity of the panel of cell 
lines. We simultaneously amplified eight short tandem repeat loci, in a multiplex PCR reaction 
(Promega PowerPlex 1.2 System) and used the ATCC and DMSZ databases for comparison, where 
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possible. In addition, gain and loss of expression of particular subtype markers, described by 
Hollestelle et al.51 were confirmed by western blot as well as microarray analysis. 
Microarray comparative genomic hybridization and gene expression profiling 
All cell line and tumours were subjected to aCGH (Breakthrough Breast Cancer Research Centre) 
32K BAC array platform and profiled as previously described.23 All cell lines and 45 tumours were 
subjected to mRNA gene expression profiling. In brief expression profiling data of cases from the 
NKI were generated as previously described22 using the Human Genome Oligo Set Version 3.0 
arrays, which contains 34 580 probes representing 24 650 genes. These arrays were obtained from 
the central microarray facility at the NKI. Detailed information on the array platform and 
hybridization protocols can be found at http://microarrays.nki.nl. The RNA from the 14 Centro 
Nacional de Investigaciones Oncolo´ gicas (CNIO) tumours and all cell lines was processed using 
the Illumina Human Ref6 Chip v2, as per the manufacturer’s protocol (www.illumina.com). 
Fluorescent intensities were normalized through Bead Studio, and processed using Lumi package in 
R as previously described.20 Before data analysis the gene lists for the NKI and CNIO cohorts were 
mapped to the human genome (ensembl HG18 assembly 49). Genes with missing values or 
ambiguous mapping information were excluded. Probes with 475% flagged values were removed. 
This left 17 490 and 12 235 unambiguously mapped unique genes with known Ensembl identities 
for analysis in the NKI and CNIO cohorts, respectively. Correlation of gene expression and aCGH 
data are described previously.23,52 Data acquisition and analysis were fully Minimal Information 
About a Microarray Experiment (MIAME) compliant. For the CNIO cohort, gene expression data 
are publicly available at ArrayExpress http://www.ebi.ac.uk/microarray-as/ae/ (accession number: 
E-TABM-543). For details of the NKI cohort, see Turner et al.23 
Cell lines, compounds and siRNA 
Cell lines were grown and transfected with SMARTpool siRNAs using Dharmafect 3 (DF3), 
Dharmafect 4 (DF4) (Dharmacon), Oligofectamine, Lipofectamine 2000 or RNAiMAX 
(Invitrogen). The custom library was obtained in four 96-well plates from Dharmacon. Each well in 
this library contained a SMARTpool of four distinct siRNA species targeting different sequences of 
the target transcript. Each plate included four wells each with Mock (transfection lipid only), 
siControl Pool1, siControl Pool2 and PLK1, Dharmacon as negative and positive controls. 
Correlation of siRNA Z-score with gene expression and aCGH data  
The correlation between siRNA Z-score and normalized gene expression was examined for genes 
where siRNA caused significant loss of viability (Zo_2). Z-score was compared with normalized 
gene expression using Pearson correlation coefficient. A gene was taken as being significantly 
correlated if the Pearson correlation coefficient was significantly different to the null hypothesis 
(Po0.05), the correlation was inverse, and the variation in gene expression between cells lines were 
significantly different as assessed by one-way analysis of variance. The number of cases harbouring 
amplifications, gains losses and deletions which also corresponded with Z-score hits in the same 
cell line was also calculated as previously described.52 
Immunoblotting 
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Protein lysates were prepared using RIPA lysis buffer (50 nM Tris pH 8.0, 150mM NaCl, 0.1% 
SDS, 0.1% deoxycholic acid (DOC), 1% TritonX-100, 50mM NaF, 1mM Na3VO4and protease 
inhibitors). Protein concentrations were measured using BioRad Protein Assay Reagent (BioRad, 
Hemel Hempstead, UK). Antibodies targeting the following were used as per manufacturer’s 
instructions: Actin, TFAP2C sc-12763 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Cleaved 
PARP 19F4, ERBB2 29D8, ERBB3 1B2 (Cell Signalling, Danvers, MA, USA). All secondary 
antibodies used for western blot analysis were horseradish peroxidase-conjugated. 
Protein bands were visualised using ECL (GE Healthcare, Cardiff, UK) and MR or XAR film 
(Kodak). 
Validation of gene silencing by siRNA Validation of RNAi gene silencing was determined by 
western blotting and by viability assays of silencing effects with individual siRNA duplexes 
(siGENOME, Dharmacon). Protein lysates were collected 48–72 h following transfection of 
individual siRNA for western blot analysis. 
Individual siRNA sequences that were on target for TFAP2C were 50-
GUAAACCAGUGGCAGAAUA-30, 50-CGACAUGCCUCACCAGAUG-30, 50-
ACACUGGAGUCGCCGAAUA-30 , for ERBB2 were; 50-GGACGAAUUCUGCACAAUG-30 , 
50-CUACAACACAGACACGUUU-30, 50-AGACGAAGCAUACGUGAUG-30, for ERBB3 
were: 50-GCAGUGGAUUCGAGAAGUG-30, 50-AGAUUGUGCUCACGGGACA-30, 50-
GUGGAUUCGAGAAGUGACA-30 and 50-GCGAUGCUGAGAACCAAUA-30 . All siRNA 
identities are available via the Dharmacon website (http://www.dharmacon.com). 
Survival assays 
For measurement of sensitivity to lapatinib, canertinib and BIBW2992 treatment, cells were plated 
in 96-well plates and exposed to the drug at the indicated concentrations. Cells were dosed at 24 and 
96 h. After 7 days, cell viability was measured using CellTiter Glo Luminescent Cell Viability 
Assay (Promega). Surviving fractions were calculated and drug sensitivity curves plotted as 
previously described using Prism.53 
Caspase activity assay 
The ApoTox Glo triplex assay (Promega) was used to assess caspase 3/7 activity and viability as 
per the manufacturer’s instructions. Cells were reverse transfected with siRNA (Dharmacon) using 
Lipofectamine 2000 (Invitrogen). Cells were plated in 96-well plates at a density of 20 000 cells per 
well. Twenty-four, and 96 h post transfection, caspase 3/7 activity and viability effects were 
assessed, respectively. 
Immunohistochemistry 
Cell line microarray blocks containing three representative replicate cores from each cell line were 
prepared, cut and subjected to immunohistochemical analysis with antibodies against ER, 
progesterone receptor, ERBB2, EGFR, and TFAP2C. All markers were scored by JR-F blinded to 
the identity of the samples. 
Chromogenic in situ hybridization 
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The CISH probe for TFAP2C was constructed and optimized on the cell line microarray as 
previously described.54 RPCI tiling path clones were purchased from Source Bioscience: RP5-
897D18, RP5-843L14 and RP4-539E24. 
Statistical analysis 
Statistical analysis of aCGH and gene expression data was performed with Excel and GraphPad 
Prism version 5.01 (GraphPad Software, La Jolla, CA, USA). 
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